- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe myoclonic epilepsy in infancy (SMEI)
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Stiripentol – March 2020
Stiripentol: Capsule 250 mg, Capsule 500mg, Powder for oral suspension 250 mg, Powder for oral suspension 500 mg; Diacomit®
Last updated
3 July 2020